首页 | 官方网站   微博 | 高级检索  
     

司帕沙星治疗耐多药肺结核疗效观察
引用本文:黄朝生,吴春城.司帕沙星治疗耐多药肺结核疗效观察[J].中国抗生素杂志,2000,25(4):302-303,316.
作者姓名:黄朝生  吴春城
作者单位:茂名市慢性病防治医院,茂名,525000
摘    要:评价司帕沙星对耐多药肺结核(MDR-PTB)的疗效与安全性,将104例MDR-PTB患者随机分为两组,以氧氟沙星作为对照。治疗组52例均采用3SHRZE+SPLX/9HRE+OFLX方案治疗,疗程均为12个月。疗程结束时,治疗组痰转阴率92.31%。明显高于对照组69.23%(0.01〈P〈0.05);治疗2个月时治疗组痰菌转阴率非常显著(P〈0.01),表明司帕沙星是目前氟喹诺酮类中治疗MDR-

关 键 词:肺结核  药物疗法  多药耐药性  司帕沙星

Observation of the clinical efficacy of sparfloxacin in the treatment of multiple drug resistance pneumonial tuberculosis
Huang Chao-sheng,Wu Chun-cheng.Observation of the clinical efficacy of sparfloxacin in the treatment of multiple drug resistance pneumonial tuberculosis[J].Chinese Journal of Antibiotics,2000,25(4):302-303,316.
Authors:Huang Chao-sheng  Wu Chun-cheng
Abstract:The clinical efficacy of sparfloxacin (SPLX) combined with other antituberrculosis agents in the treatment of multiple drug resistance pneumonial tuberculosis (MDR PTB) was studied. Fifty two cases are randomly divided into two groups using domestic made ofloxacin (OFLX) as comparison. The dosage regimen in the 12 month course of the treatment group is composed of streptomycin (S) isoniazid (H) rifampin (R) pyrazinamide (Z) ethambutol (E) SPLX for three months and HRE SPLX for nine months; and the control group was SHRZE OFLX for three months and HRE OFLX for nine months. At the end of the treatment, the TB sputum negative rate of the treatment group is 92.31% while the control group is 69.23% (0.01< P <0.05). At the time of two months, the difference of the sputum negative rate in the treatment group is statistically significant when compared with the control group ( P <0.01). The findings indicated that sparfloxacin is an effective drug for MDR PTB among other quinolones.
Keywords:Tubercuosis  Lung  MDR  Quinolone  Sparfloxacin  Clinical efficacy
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号